|
US10584A
(en)
|
|
1854-02-28 |
|
Bank-lock |
|
US101A
(en)
|
|
1836-12-06 |
|
Method of jcakibtg and furling iw sails fob ships |
|
DE122007000079I2
(de)
|
1996-07-24 |
2010-08-12 |
Celgene Corp |
Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
|
|
CA2287387C
(en)
|
1997-05-14 |
2010-02-16 |
Sloan-Kettering Institute For Cancer Research |
Methods and compositions for destruction of selected proteins
|
|
KR20010033248A
(ko)
|
1997-12-17 |
2001-04-25 |
폴락 돈나 엘. |
인테그린 수용체 길항제
|
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
|
EP1176959B1
(en)
|
1999-05-05 |
2006-03-08 |
Merck & Co., Inc. |
Novel prolines as antimicrobial agents
|
|
MXPA02012605A
(es)
|
2000-06-28 |
2003-05-14 |
Squibb Bristol Myers Co |
Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
|
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
WO2002020740A2
(en)
|
2000-09-08 |
2002-03-14 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
RU2298554C2
(ru)
|
2000-09-19 |
2007-05-10 |
Бристол-Маерс Сквибб Компани |
Конденсированные гетероциклические сукцинимидные соединения
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
JP2005507363A
(ja)
|
2001-02-16 |
2005-03-17 |
イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー |
血管新生阻害トリペプチド、組成物およびそれらの使用方法
|
|
HN2002000136A
(es)
|
2001-06-11 |
2003-07-31 |
Basf Ag |
Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
|
|
ES2366430T3
(es)
|
2001-06-20 |
2011-10-20 |
Takeda Pharmaceutical Company Limited |
Método para fabricar comprimidos.
|
|
NZ531294A
(en)
|
2001-08-06 |
2005-11-25 |
Childrens Medical Center |
Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
|
|
US7030141B2
(en)
|
2001-11-29 |
2006-04-18 |
Christopher Franklin Bigge |
Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
|
|
US20060004029A1
(en)
|
2002-08-30 |
2006-01-05 |
Akihiko Tsuruoka |
Nitrogen-containing aromatic derivatives
|
|
MXPA06015169A
(es)
|
2004-07-08 |
2007-08-21 |
Warner Lambert Co |
Moduladores de androgenos.
|
|
CN100383139C
(zh)
|
2005-04-07 |
2008-04-23 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
|
|
WO2006113942A2
(en)
|
2005-04-20 |
2006-10-26 |
Schering Corporation |
Method of inhibiting cathepsin activity
|
|
UA91560C2
(ru)
|
2005-08-31 |
2010-08-10 |
Селджин Корпорэйшн |
Соединения ряда изоиндолимидов, их композиция и применение
|
|
AU2007226715A1
(en)
|
2006-03-03 |
2007-09-20 |
Novartis Ag |
N-formyl hydroxylamine compounds
|
|
WO2007127010A2
(en)
|
2006-03-29 |
2007-11-08 |
The Regents Of The University Of California |
Diarylthiohydantoin compounds
|
|
AU2007275415A1
(en)
|
2006-07-20 |
2008-01-24 |
Ligand Pharmaceuticals Incorporated |
Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
CL2007002513A1
(es)
|
2006-08-30 |
2008-04-04 |
Celgene Corp Soc Organizada Ba |
Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
|
|
RU2448101C2
(ru)
|
2006-08-30 |
2012-04-20 |
Селджин Корпорейшн |
5-замещенные изоиндолиновые соединения
|
|
CA2668286C
(en)
|
2006-11-03 |
2014-09-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
|
US8415340B2
(en)
|
2007-07-25 |
2013-04-09 |
Bristol-Myers Squibb Company |
Triazine kinase inhibitors
|
|
MX2010001125A
(es)
|
2007-07-31 |
2010-09-30 |
Androscience Corp |
Composiciones incluyendo receptor androgeno de degradacion (ard) ponteciadores y metodos de tratamiento profilactico o terapeutico de trastornos de la piel y la caida de cabello.
|
|
PT2358697E
(pt)
|
2008-10-29 |
2016-02-03 |
Celgene Corp |
Compostos de isoindolina para utilização no tratamento do cancro
|
|
US8617588B2
(en)
|
2009-03-09 |
2013-12-31 |
Spi Pharma, Inc. |
Highly compactable and durable direct compression excipients and excipient systems
|
|
WO2010141805A1
(en)
|
2009-06-05 |
2010-12-09 |
Janssen Pharmaceutica Nv |
Heterocyclic amides as modulators of trpa1
|
|
AU2010273220B2
(en)
|
2009-07-13 |
2015-10-15 |
President And Fellows Of Harvard College |
Bifunctional stapled polypeptides and uses thereof
|
|
AR078793A1
(es)
|
2009-10-27 |
2011-12-07 |
Orion Corp |
Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
|
|
PL3202460T3
(pl)
|
2010-02-11 |
2019-12-31 |
Celgene Corporation |
Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
|
|
CN103153335A
(zh)
|
2010-06-30 |
2013-06-12 |
布兰代斯大学 |
小分子靶定的蛋白质降解
|
|
WO2012040527A2
(en)
|
2010-09-24 |
2012-03-29 |
The Regents Of The University Of Michigan |
Deubiquitinase inhibitors and methods for use of the same
|
|
CA2823837A1
(en)
|
2010-12-07 |
2012-06-14 |
Yale University |
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
|
|
WO2012090104A1
(en)
|
2010-12-31 |
2012-07-05 |
Kareus Therapeutics, Sa |
Methods and compositions for designing novel conjugate therapeutics
|
|
WO2012143599A1
(en)
|
2011-04-21 |
2012-10-26 |
Orion Corporation |
Androgen receptor modulating carboxamides
|
|
AU2012249491B2
(en)
|
2011-04-29 |
2016-12-15 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
KR102668696B1
(ko)
|
2012-01-12 |
2024-05-29 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
|
US20140079636A1
(en)
|
2012-04-16 |
2014-03-20 |
Dinesh U. Chimmanamada |
Targeted therapeutics
|
|
WO2013170147A1
(en)
|
2012-05-11 |
2013-11-14 |
Yale University |
Compounds useful for promoting protein degradation and methods using same
|
|
KR20210033067A
(ko)
*
|
2012-06-04 |
2021-03-25 |
파마싸이클릭스 엘엘씨 |
브루톤 타이로신 키나아제 저해제의 결정 형태
|
|
WO2014015157A2
(en)
|
2012-07-19 |
2014-01-23 |
Philadelphia Health & Education Corporation |
Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
|
NL2011274C2
(en)
|
2013-08-06 |
2015-02-09 |
Illumicare Ip B V 51 |
Groundbreaking platform technology for specific binding to necrotic cells.
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
EP3738594A1
(en)
|
2013-09-10 |
2020-11-18 |
Madrigal Pharmaceuticals, Inc. |
Targeted therapeutics having an hsp90 ligand as binding moiety
|
|
WO2015114314A1
(en)
|
2014-01-28 |
2015-08-06 |
Cipla Limited |
Pharmaceutical composition comprising abiraterone
|
|
JP6576942B6
(ja)
|
2014-03-03 |
2019-11-27 |
マドリガル ファーマシューティカルズ インコーポレイテッド |
標的治療薬
|
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
RU2738833C9
(ru)
|
2014-04-14 |
2022-02-28 |
Арвинас, Оперэйшнз, Инк. |
Имидные модуляторы протеолиза и способы их применения
|
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
WO2016081472A1
(en)
|
2014-11-21 |
2016-05-26 |
Biohaven Pharmaceutical Holding Company Ltd. |
Sublingual formulation of riluzole
|
|
WO2016097071A1
(en)
|
2014-12-18 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Estrogen receptor modulators and uses thereof
|
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
GB201504314D0
(en)
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
|
EP3270917A4
(en)
|
2015-03-18 |
2018-08-08 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
GB201506872D0
(en)
|
2015-04-22 |
2015-06-03 |
Ge Oil & Gas Uk Ltd |
Novel compounds
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CA2988414C
(en)
|
2015-06-04 |
2023-09-26 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
BR112017028269A2
(pt)
|
2015-07-13 |
2018-09-04 |
Arvinas Inc |
composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
KR101859074B1
(ko)
|
2016-01-28 |
2018-05-18 |
이화여자대학교 산학협력단 |
신규한 글라이신 아미드 화합물 또는 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 포함하는 소듐 채널 활성 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
CN109152933B
(zh)
|
2016-04-21 |
2022-12-02 |
生物风险投资有限责任公司 |
诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
|
|
US10865205B2
(en)
|
2016-04-22 |
2020-12-15 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use
|
|
EP3445765A4
(en)
|
2016-04-22 |
2019-09-18 |
Dana Farber Cancer Institute, Inc. |
DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US20180072711A1
(en)
|
2016-09-15 |
2018-03-15 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
CN110506039A
(zh)
|
2016-10-11 |
2019-11-26 |
阿尔维纳斯股份有限公司 |
用于雄激素受体靶向降解的化合物和方法
|
|
WO2018098280A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
|
|
FR3064633B1
(fr)
|
2017-03-28 |
2019-04-12 |
Ecole Polytechnique |
Nouveaux composes de type dithiospirocetals et leur utilisation
|
|
WO2018204422A1
(en)
|
2017-05-01 |
2018-11-08 |
Spg Therapeutics, Inc. |
Tripartite androgen receptor eliminators, methods and uses thereof
|
|
KR102119465B1
(ko)
|
2017-09-20 |
2020-06-08 |
(주)아모레퍼시픽 |
트리메톡시 페닐 화합물 및 그를 포함하는 발모 또는 육모 촉진용 조성물
|
|
CN110746399B
(zh)
|
2018-07-23 |
2022-04-22 |
上海美志医药科技有限公司 |
具有降解雄激素受体活性的化合物
|
|
WO2020047487A1
(en)
|
2018-08-31 |
2020-03-05 |
The Regents Of The University Of California |
Methods for treating cancer with rorgamma inhibitors and statins
|
|
CN113473987B
(zh)
|
2018-12-19 |
2024-09-03 |
细胞基因公司 |
被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
|
|
CN113453681B
(zh)
|
2018-12-19 |
2024-10-11 |
细胞基因公司 |
经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
US11547759B2
(en)
|
2019-01-30 |
2023-01-10 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
EP3917916A4
(en)
|
2019-01-30 |
2022-12-14 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
WO2020198712A1
(en)
|
2019-03-28 |
2020-10-01 |
Essa Pharma, Inc. |
Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
|
|
CN114269331A
(zh)
|
2019-03-28 |
2022-04-01 |
埃萨制药股份有限公司 |
雄激素受体调节剂和用作蛋白水解靶向嵌合体配体的方法
|
|
WO2020211822A1
(zh)
|
2019-04-18 |
2020-10-22 |
成都海创药业有限公司 |
一类靶向降解雄激素受体的双功能嵌合体杂环化合物及其用途
|
|
US12331061B2
(en)
|
2019-04-18 |
2025-06-17 |
Accutar Biotechnology Inc. |
Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereof
|
|
EP3971176A4
(en)
|
2019-05-17 |
2023-01-25 |
Hinova Pharmaceuticals Inc. |
AR AND BET AROMATIC AMINE TARGETING PROTEIN DEGRADATION CHIMERIC COMPOUND AND USE THEREOF
|
|
WO2021055756A1
(en)
|
2019-09-19 |
2021-03-25 |
The Regents Of The University Of Michigan |
Spirocyclic androgen receptor protein degraders
|
|
JP7307796B2
(ja)
|
2019-09-23 |
2023-07-12 |
アキュター バイオテクノロジー インコーポレイテッド |
アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用
|
|
WO2021061644A1
(en)
|
2019-09-23 |
2021-04-01 |
Accutar Biotechnology Inc. |
Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
|
|
EP4034114A4
(en)
|
2019-09-23 |
2023-07-26 |
Accutar Biotechnology Inc. |
NEW UREAES HAVING ANDROGEN RECEPTOR DEGRADING ACTIVITY AND THEIR USES
|
|
KR20220087482A
(ko)
|
2019-10-22 |
2022-06-24 |
아비나스 오퍼레이션스, 인코포레이티드 |
전립선암 치료 방법
|
|
CN114829342A
(zh)
|
2019-12-23 |
2022-07-29 |
上海济煜医药科技有限公司 |
一种蛋白降解剂化合物的制备方法和应用
|
|
CN113582974B
(zh)
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
KR20230015934A
(ko)
|
2020-05-12 |
2023-01-31 |
아비나스 오퍼레이션스, 인코포레이티드 |
전립선암 치료 방법
|
|
CR20230007A
(es)
|
2020-06-12 |
2023-06-01 |
Shanghai Jemincare Pharmaceuticals Co Ltd |
Compuesto de ftalazinona, y método de preparación y uso médico de este.
|
|
KR20230027066A
(ko)
|
2020-06-24 |
2023-02-27 |
셀진 코포레이션 |
세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
|
|
JP7778095B2
(ja)
|
2020-06-24 |
2025-12-01 |
セルジーン コーポレーション |
セレブロン結合化合物、その組成物及びそれによる治療方法
|
|
KR20230027214A
(ko)
|
2020-06-24 |
2023-02-27 |
셀진 코포레이션 |
세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
|
|
CN117327059A
(zh)
|
2020-07-08 |
2024-01-02 |
北京泰德制药股份有限公司 |
抑制并诱导蛋白降解的化合物
|
|
WO2022048605A1
(zh)
|
2020-09-04 |
2022-03-10 |
南昌奥瑞药业有限公司 |
一种杂环化合物、其制备方法、中间体、组合物以及应用
|
|
CN114163444B
(zh)
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
JP2023547084A
(ja)
|
2020-10-21 |
2023-11-09 |
アルビナス・オペレーションズ・インコーポレイテッド |
アンドロゲン受容体タンパク質の標的分解のための化合物および方法
|
|
US20220144809A1
(en)
|
2020-11-06 |
2022-05-12 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
|
|
CN116529248B
(zh)
|
2020-11-25 |
2025-10-17 |
西藏海思科制药有限公司 |
一种苯环衍生物及其组合物和药学上的应用
|
|
JP2023552818A
(ja)
|
2020-12-11 |
2023-12-19 |
アルビナス・オペレーションズ・インコーポレイテッド |
前立腺癌を治療する方法
|
|
TWI813106B
(zh)
|
2020-12-30 |
2023-08-21 |
財團法人工業技術研究院 |
雄性激素受體結合分子及其用途
|
|
CN114853846A
(zh)
|
2021-02-04 |
2022-08-05 |
苏州国匡医药科技有限公司 |
一种雄激素受体降解剂及其应用
|
|
US20240190874A1
(en)
|
2021-03-03 |
2024-06-13 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
|
US12016847B2
(en)
|
2021-03-12 |
2024-06-25 |
Bristol-Myers Squibb Company |
Methods of treating prostate cancer
|
|
CN116891457A
(zh)
|
2022-04-11 |
2023-10-17 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
US20250248999A1
(en)
|
2022-04-21 |
2025-08-07 |
Arvinas Operations, Inc. |
Bavdegalutamide and combinations thereof for use in treating prostate cancer
|
|
CN117065022A
(zh)
|
2022-05-17 |
2023-11-17 |
海创药业股份有限公司 |
一种治疗三阴乳腺癌的药物
|
|
CN117024390B
(zh)
|
2023-08-09 |
2025-11-11 |
中国海洋大学 |
一种Cdc20小分子配体化合物及其降解剂的应用
|